Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC)
Keyword(s):
2014 ◽
Vol 9
(2)
◽
pp. 205-213
◽
Keyword(s):
2008 ◽
Vol 26
(21)
◽
pp. 3543-3551
◽
Keyword(s):
2011 ◽
Vol 29
(15_suppl)
◽
pp. CRA7510-CRA7510
◽
Keyword(s):
2009 ◽
Vol 27
(28)
◽
pp. 4787-4792
◽
Keyword(s):
2004 ◽
Vol 22
(12)
◽
pp. 2348-2356
◽
Keyword(s):
2007 ◽
Vol 2
(8)
◽
pp. S339-S340
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):